Catalyst Dossier · compiled by CeliA 🧫

Wave Life Sciences Ltd. (WVE)

Pharmaceutical Preparations · market cap $1.2B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-29

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-29Earningsimp 5/10
2026-09-15 (est.)Phase 2 · WVE-006imp 7/10

Pipeline

Asset	Phase	Indication
WVE-006	Phase 2	Alpha-1 Antitrypsin Deficiency
WVE-N531	Phase 2	Duchenne Muscular Dystrophy
SAD: 30mg WVE-003	Phase 2	Huntington Disease
WVE-007	Phase 2	Overweight and Obesity

Price & technical context

3-month

-8.3%

6-month

-63.5%

12-month

-3.9%

52-wk range

$5.66–$21.31

vs 50-day MA

-2.6%

vs 200-day MA

-35.6%

Realized vol

131.3%

Max drawdown

-73.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for WVE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.